Those responses lasted for a median of 13.8 months, Seagen and Astellas said. RELATED: Xtandi raise, Padcev lift and a women's health surprise: Astellas outlines $17B 5-year plan Padcev's new approvals put the drug one step closer to its blockbuster ambitions. SVB Leerink's Andrew Berens has said the med could hit $1.32 billion in peak sales across all its potential nods in previously treated bladder cancer. Meanwhile, Wall Street predicts that number could swell to $2.8 billion in 2030—provided Padcev makes its way up the treatment chain to newly diagnosed bladder cancer patients.